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إدارة عالج ناجحة حلالة مهملة من اعتالل الداء السيستيين الكلوي
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abstract: Cystinosis is a rare metabolic disorder characterised by lysosomal cystine accumulation leading to 
multi-organ damage; clinically, the kidneys are the first organ affected. Respiratory insufficiency caused by overall 
respiratory muscle myopathy is a life-threatening complication. Treatment with cysteamine should be initiated 
rapidly and continued lifelong to prolong renal function and protect the extra-renal organs. We report the case 
of a four-year-old Omani girl, diagnosed with infantile nephropathic cystinosis at 21 months. Cysteamine was 
prescribed but with no compliance to medications. She presented to the Child Health Department of Sultan Qaboos 
University Hospital, Oman, two years later with severe failure to thrive, electrolyte disturbance and respiratory 
failure. The hypoventilation and early respiratory dysfunction, due to intercostal and diaphragm myopathy, was 
treated by non-invasive positive-pressure ventilation. The patient was discharged after four months of intensive 
rehabilitation with no ventilator support. No standard treatment options have yet been established for respiratory 
dysfunction in cystinosis.
Keywords: Cystinosis; Cysteamine; Continuous Positive Airway Pressure; Positive-Pressure Ventilation; Failure to 
Thrive; Pediatric Intensive Care Units; Case Report; Oman.
الكلى هي  اأع�صاء متعددة. �رشيريا،  اإىل �رشر  يوؤدي  احلال مما  اجل�صيم  ال�صي�صتني يف  يتميز برتاكم  نادر  اأي�صي  ا�صطراب  ال�صي�صتيني هو  الداء  امللخ�ص: 
اأول الأع�صاء تاأثراً. الق�صور التنف�صي الناجم عن العتلل الع�صلي العام يف ع�صلت التنف�س، هو من امل�صاعفات التي تهدد احلياة . ال�رشوع يف بداأ علج 
"Cysteamine" ب�رشعة وا�صتمرارة مدى احلياة يطيل بقاء وظيفة الكلى وحماية الأجهزة خارج الكلية. نعر�س هنا  تقرير حلالة فتاة عمانية تبلغ من 
العمر 4 �صنوات، مت ت�صخي�صها باإعتلل الداء ال�صي�صتيني الكلوي الطفويل يف عمر 21 �صهرا. كان هناك عدم اأمتثال لأخذ دواء "Cysteamine" الذي كان 
مقررا اأعطاءة. قدمت الطفلة اإىل ق�صم �صحة الطفل يف م�صت�صفى جامعة ال�صلطان قابو�س يف �صلطنة عمان ، و هي تعاين من ف�صل حاد يف النمو، و ا�صطرابات 
يف الأملح ، و ف�صل يف اجلهاز التنف�صي . مت علج نق�س التهوية و �صعف اجلهاز التنف�صي املبكر نتيجة اأعتلل الع�صلت الوربية و احلجاب احلاجز ، بوا�صطة 
جهاز تهوية اإيجابي ال�صغط غري غري با�صع )NIPPV(. خرجت املري�صة بعد اأربعة اأ�صهر من اإعادة التاأهيل املكثف مع عدم وجود دعم التنف�س ال�صناعي 
. مل يتم حتى الآن حتديد مقيا�س للخيارات العلجية يف حالت اختلل وظيفة اجلهاز التنف�صي يف الداء ال�صي�صتيني . 
مفتاح الكلمات: تهوية اإيجابية ال�صغط؛ غري با�صع؛ الف�صل يف النمو؛ الداء ال�صي�صتيني؛ �صغط اإيجابي م�صتمر ملجرى الهواء؛ وحدة العناية املركزة للأطفال؛ 
تقرير حالة، عمان.
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CASE REPORT
Cystinosis is an autosomal recessive disorder characterised by an accumulation of the amino acid cystine in lysosomes 
throughout the body. CTNS, the responsible gene, is 
defective in this disease. Usually, this gene encodes 
the lysosomal cystine carrier cystinosin, which is a 
lysosomal transport molecule needed to carry cystine 
out of the cells. It was cloned in 1998 and is located on 
the short arm of the chromosome 17p13.1,2 In virtually 
all tissues, cystine accumulation causes multi-organ 
damage, with the kidneys being clinically the first 
affected. Cystinosis generally manifests in infancy as 
Fanconi syndrome with severe renal proximal tubular 
dysfunction. End-stage disease develops around 
the age of 10 years without specific therapy using 
the cystine-depleting agent, cysteamine.2 Cystine 
accumulation has also been detected in the muscular 
tissue; the first case of severe myopathy in cystinosis 
was reported in 1988.3 
The association of nephropathic cystinosis with 
progressive distal vacuolar myopathy was described 
in more detail in 1994.4 Anikster et al. studied the 
pulmonary function and myopathy of 12 patients with 
nephropathic cystinosis and concluded that restrictive 
pulmonary disease due to overall respiratory muscle 
dysfunction is characteristic of the disease.5 It usually 
develops after patients reach 10 years of age in the 
majority of those not treated with cysteamine.2
The aminothiol cysteamine depletes lysosomal 
cystine content by a disulfide exchange reaction 
with cystine, resulting in the formation of cysteine-
cysteamine mixed disulfide and cysteine. This exits 
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the lysosomes via a system c transporter and the 
remaining cysteine via a cysteine carrier.6,7 The system 
c transporter was recently identified to be the PQLC2 
transporter.8
We report a case of cystinosis with myopathy whose 
hypercapnic respiratory failure was treated with non-
invasive positive-pressure ventilation (NIPPV). Due to 
this treatment modality, the patient was moved from 
prolonged admission in the Paediatric Intensive Care 
Unit (PICU) and gradually weaned from NIPPV to 
nocturnal ventilation. She was weaned off ventilation 
completely after approximately two months.
Case Report
This Omani female child had been previously reported 
as the first case of nephropathic cystinosis in Oman 
when she was 21 months old.9 At that time, the 
patient was started on cysteamine (30 mg/Kg/day) 
but the family had poor compliance to medications 
and she was lost to follow-up for the following two 
years.9 Subsequently, the patient presented to the 
Child Health Department of Sultan Qaboos Hospital, 
Oman, at the age of four years with a severe failure to 
thrive (weighing 6.1 Kg and below the third centile), 
pallor, metabolic acidosis, hypophosphataemia, 
hypokalaemia and a severe chest deformity with 
rachitic manifestations [Figure 1]. Additionally, she 
presented with bronchopneumonia with respiratory 
failure which required her to be admitted to the PICU 
for respiratory support [Figure 2].
During her three-month stay in the PICU, she was 
ventilated using pressure-regulated volume control 
(PRVC) mode. The patient was ventilated with high 
ventilator settings for a short period, but for most of 
the time in the PICU she was ventilated with moderate 
ventilator settings. She remained on low ventilator 
settings after two failed attempts to extubate her to 
continuous positive airway pressure (CPAP). The 
extubation failed because of respiratory dysfunction 
due to myopathy, the chest deformity, electrolyte 
disturbance, feeding intolerance and infections.
A multidisciplinary team was involved in her 
treatment. It was decided to start the patient gradually 
on cysteamine until a good response was seen. During 
this time, efforts were made to increase her weight 
using total parenteral nutrition and a high-caloric 
formula through continuous nasogastric tube feeding; 
this was successful and the patient gained 3 Kg in 
weight. Additionally, her electrolytes were corrected 
and she spent time in physiotherapy and play therapy 
with familial support. CPAP was begun after three 
months of conventional ventilation.
Whilst on CPAP (at a flow of 12 and 40% fraction 
of inspired oxygen [FiO2]), the patient was conscious, 
 
Figure 1: A photograph of the child on presentation 
with severe failure to thrive and severe muscle wasting. 
Note the small rachitic deformed chest.
 
Figure 2: Chest X-ray on admission with extensive 
bilateral infiltration showing the hypoplastic chest and 
rachitic rosary. 
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Figure 3: A photograph of the patient after treatment. 
Note the marked increase in weight and the 
improvement of the muscle wasting and rachitic rosary. 
A nasogastric tube was used for continuous feeding.
 
Figure 4: Chest X-ray before discharge showing the 
almost completely clear bilateral lung fields with 
improvement of the rachitic  rosary.
alert, tachypnoeic (at 50 breaths/min), with subcostal 
recession and poor bilateral air entry. An arterial 
blood gas (ABG) test showed partial compensated 
respiratory acidosis with a pH of 7.30; partial pressure 
of carbon dioxide (PCO2) at 7 kilopascals (kPA); 
bicarbonate (HCO3) of 25.2, and partial pressure of 
oxygen (PO2) at 9.6 kPA.
After 24 hours, the patient began ventilation 
using the BiPap® Vision® Ventilatory Support System 
(VVS, Respironics, Philips Healthcare, Andover, 
Massachusetts, USA) at inspiratory positive airway 
pressure (IPAP)/expiratory positive airway pressure 
(EPAP) setting of 16/7, rate of 25 and 40% FiO2. 
Clinically, the patient was conscious and alert with 
improvement in air entry. Her ABG test showed a 
pH of 7.42; PCO2 at 6.9 kPA; HCO3 of 31, and PO2 
at 10 kPA. After two weeks, the BiPap® VSS settings 
were changed to an IPAP/EPAP setting of 12/6, a rate 
of 20 and 30% FiO2. Initially, her weight increased 
incrementally at a rate of almost 0.4 Kg per day due 
to the effects of the high calorie intake, medication 
and electrolyte supplementation. On follow-up of her 
respiratory status, there was a significant improvement 
of respiratory stress and chest air entry with the 
ABG test recording a pH of 7.35, PCO2 at 5.4 kPA, a 
HCO3 of 25 and PO2 at 10.8 kPA. From that point, the 
patient was gradually weaned from the BiPap® VSS; 
within two weeks, she was only using the ventilation 
system during her sleep. During the day, the patient 
maintained saturation on room air. 
After a further two weeks, the patient had gained 
0.6 Kg and was weaned completely from the BiPap® 
VSS even while asleep. She displayed no early morning 
lethargy, cyanosis or tachypnoea [Figure 3]. Her ABG 
test in the morning recorded a pH of 7.4; PCO2 at 4.2 
kPA; HCO3 of 20.1, and PO2 at 10.9 kPA. Before she 
was discharged, a chest X-ray was performed which 
showed a marked improvement [Figure 4].
The patient was discharged with no ventilator 
support after four months of intensive rehabilitation, 
repeated counselling and familal support. Nutritional 
support was continued with a feeding tube at home. 
The patient was followed-up and her respiratory 
status was closely monitored; she continued to show 
improvement in her respiratory dysfunction with 
normal blood gas results.
Discussion
Cystinosis is a rare metabolic disorder and the 
respiratory insufficiency caused by the overall 
respiratory myopathy is a severely invalidating and 
sometimes life-threatening complication.5 The 
current patient, initially diagnosed at 21 months, 
presented—after two years of non-compliance to the 
cystine-depleting agent, cysteamine—with failure 
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to thrive, myopathy, respiratory dysfunction and 
failure and other associated conditions. There was 
evidence of diaphragmatic myopathy as the patient 
was hypoventilating, as proven by the ABG tests 
and clinical evidence of emaciated intercostals, 
paradoxical chest movements during the first few 
days of admission and the preference to remain in a 
sitting position even during sleep. This improved with 
cysteamine and other modalities of support.
Cysteamine is the only available treatment for 
cystinosis, slowing the deterioration of renal function 
and the occurrence of extra-renal complications. It can 
deplete cystine from the muscles and can stop or delay 
the myopathy; however, it should be started early and 
continued for the rest of the patient’s life. Although 
no study has yet addressed the question of whether 
cysteamine is an effective treatment for cystinosis-
associated myopathy, Gahl et al. demonstrated that 
cysteamine is able to deplete muscular tissue of 
cystine.3 
Through multidisciplinary teamwork—with 
the reintroduction of cysteamine, the correction 
of the electrolyte disturbance, physiotherapy, play 
therapy, feeding supplementation of a high-caloric 
formula through a nasogastric tube and a change of 
respiratory support to BiPap® VSS—the patient’s 
general condition and respiratory function improved 
and she was discharged from the PICU. The patient 
had been tachypnoeic and showing signs of distress 
even with CPAP ventilator support and her blood 
pH was suboptimal due to a high carbon dioxide 
concentration. The patient initially awoke drowsy in 
the mornings due to carbon dioxide retention. After 
treatment, she was fully conscious and alert in the 
mornings with normal blood pH and carbon dioxide 
levels and no signs of respiratory distress despite no 
ventilator support. It was evident that her carbon 
dioxide levels had reduced by almost 20% even after 
the BiPap® VSS was discontinued.
Eden et al. reported the  use of nocturnal NIPPV 
in a 38-year-old male suffering from respiratory 
dysfunction due to cystinosis. The diagnosis was 
initially made when the patient was 2 years old and 
treatment was started at the age of 25 years.10 Although 
mostly used for other disease processes, NIPPV can 
improve the patient’s quality of life and reduce the 
hospital stay and expenses for cases of cystinosis and 
respiratory dysfunction, as can be evidenced from the 
current reported case.
Conclusion
Cysteamine is currently the only available treatment 
for cystinosis. It is assumed that cysteamine depletes 
the accumulation of cystine in the muscles. In cases 
of established respiratory dysfunction, no treatment 
options have so far been describe. As evidenced in the 
case of nephropathic cystinosis reported here, NIPPV 
can be used in cases of myopathy for the correction of 
hypoventilation and respiratory dysfunction.
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